Stoke Therapeutics (STOK) Cash from Investing Activities (2018 - 2026)

Stoke Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $50.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 271.88% year-over-year to $50.7 million; the TTM figure through Mar 2026 stood at -$149.8 million (down 44.22% YoY), while the FY2025 annual figure was -$186.8 million, down 73.82% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $50.7 million, up from -$61.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $67.3 million in Q3 2022, with the low at -$148.5 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is $10.0 million (2024), against an average of -$10.8 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 66459.8% in 2022, then jumped 15977.4% in 2023.
• Stoke Therapeutics' Cash from Investing Activities stood at $22.5 million in 2022, then tumbled by 34.32% to $14.8 million in 2023, then plunged by 94.46% to $819000.0 in 2024, then plunged by 7555.56% to -$61.1 million in 2025, then jumped by 183.02% to $50.7 million in 2026.
• Business Quant data shows STOK's Cash from Investing Activities at $50.7 million in Q1 2026, -$61.1 million in Q4 2025, and $9.1 million in Q3 2025.